Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 4
2005 14
2006 4
2007 8
2008 14
2009 9
2010 13
2011 12
2012 15
2013 20
2014 29
2015 17
2016 21
2017 22
2018 23
2019 18
2020 24
2021 25
2022 31
2023 27
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Wakita S, et al. Among authors: kuroda j. Blood Adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. Blood Adv. 2022. PMID: 34448807 Free PMC article.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: kuroda j. Haematologica. 2023 Mar 1;108(3):811-821. doi: 10.3324/haematol.2022.280996. Haematologica. 2023. PMID: 36200417 Free PMC article.
Bilateral Popeye's Sign.
Shibahara T, Tanaka E, Kuroda J, Nakane H. Shibahara T, et al. Among authors: kuroda j. Intern Med. 2023 Sep 15;62(18):2757-2758. doi: 10.2169/internalmedicine.1093-22. Epub 2023 Jan 15. Intern Med. 2023. PMID: 36642522 Free PMC article. No abstract available.
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. Terui Y, et al. Among authors: kuroda j. Cancer Sci. 2021 Jul;112(7):2845-2854. doi: 10.1111/cas.14937. Epub 2021 Jun 4. Cancer Sci. 2021. PMID: 33942442 Free PMC article. Clinical Trial.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S. Horigome Y, et al. Among authors: kuroda j. Ann Hematol. 2024 Feb;103(2):475-488. doi: 10.1007/s00277-023-05428-7. Epub 2023 Sep 11. Ann Hematol. 2024. PMID: 37695378 Free PMC article.
NADPH oxidase and cardiac failure.
Kuroda J, Sadoshima J. Kuroda J, et al. J Cardiovasc Transl Res. 2010 Aug;3(4):314-20. doi: 10.1007/s12265-010-9184-8. Epub 2010 Mar 31. J Cardiovasc Transl Res. 2010. PMID: 20559780 Free PMC article. Review.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, Goto H, Jackson CC, Sun H, Pacaud L, Fujikawa E, Yeh TM, Hatayama T, Aida K, Sunagawa Y, Iida S. Ri M, et al. Among authors: kuroda j. Cancer Sci. 2022 Dec;113(12):4267-4276. doi: 10.1111/cas.15556. Epub 2022 Oct 7. Cancer Sci. 2022. PMID: 36052883 Free PMC article. Clinical Trial.
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S, Chi S, Minami Y, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Morishita T, Kondo T, Yanada M, Yamamoto K, Kuroda J, Usuki K, Akahane D, Gotoh A. Katagiri S, et al. Among authors: kuroda j. Int J Mol Sci. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694. Int J Mol Sci. 2022. PMID: 35563085 Free PMC article. Review.
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 Investigators. Hosono N, et al. Among authors: kuroda j. Cancer Sci. 2023 May;114(5):2098-2108. doi: 10.1111/cas.15746. Epub 2023 Mar 1. Cancer Sci. 2023. PMID: 36793248 Free PMC article.
313 results